openPR Logo
Press release

Proteros has relocated to a tailor-made facility in Martinsried

10-24-2011 05:11 PM CET | Science & Education

Press release from: Proteros biostructures GmbH

Martinsried, October 24th 2011. Proteros biostructures GmbH is further extending its business capacities by moving into a new building in Munich-Martinsried, one of the leading Biotech locations in Germany.

After a two-year planning period, Proteros has reached an important milestone in its development by centralizing all operations within a purpose-built facility. The 4,000 square-meter of laboratory and office space, worth a total of about 15 M €, has been optimally designed for Proteros’ specific requirements in protein production, X-Ray crystallography and kinetic analytics as well as medicinal chemistry and own synthesis group. The new facilities not only provide sufficient space for Proteros’ current over eighty employees, it also would enable the company to double its work-force within the next years. In addition, the company has achieved greater flexibility to broaden its technology platform, e.g. by operating a state-of-the art mammalian cell culture unit for protein production.

The design concept of the entire building incorporates proven innovative solutions from different industries and ideally supports Proteros’ industrialized processes. All employees will work in a most ergonomic lab environment that is expected to increase the creativity and efficiency in all work flows. Furthermore, the open spatial design facilitates communication amongst the different departments and creates an inspiring working environment for Proteros’ highly qualified scientific researchers. Major focus has also been laid on enabling the personnel to operate the laboratories in a sustainable and environmentally friendly manner.

About Proteros
Proteros is a privately held company, which provides services and proprietary technologies to support integrated drug discovery within life sciences. The company accelerates and improves protein structure analysis and structure-based drug discovery with its expertise, industrialized processes and unique technologies for crystallography and fragment-based lead generation. Proteros complements its clients’ internal capabilities with external expertise and access to flexible resources. Proteros currently provides services for more than 80 pharmaceutical and biotechnology clients in North America, Europe and Asia.

Contact:
Proteros biostructures GmbH
Dr. Thomas Waldmann
Director Business Development
Bunsenstr. 7a
82152 Martinsried
Germany
Phone: +49 (0)89 700 761-0
E-Mail: business@proteros.com
Website: www.proteros.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Proteros has relocated to a tailor-made facility in Martinsried here

News-ID: 197585 • Views: 1771

More Releases from Proteros biostructures GmbH

PROTEROS ANNOUNCES SUCCESSFUL CLOSE OF FINANCING ROUND
Largest-ever Financing allows for Expansion of Drug Discovery Capabilities MARTINSRIED, GERMANY (August 6th, 2012) – Proteros biostructures GmbH (‘Proteros’) announced today that it had successfully closed a financing round of five million Euros to fund the continued expansion and growth of the company. The financing round was led by BayBG, a key equity investor for Proteros. The financing round is the third and largest investment into the firm since the inception
Proteros and Eisai Co., Ltd enter into Integrated Lead Discovery Collaboration
Martinsried (Germany), April 16, 2012. Proteros biostructures GmbH today announced that the company has entered into a research collaboration with Eisai Co., Ltd (Japan) to identify small molecule inhibitors against a target selected by Eisai in the field of immunology. Under the agreement Proteros will deliver a novel lead compound applying its integrated lead discovery platform that includes X-Ray structural biology, biophysical screening and profiling, novel fragment libraries and medicinal chemistry
Proteros announces the appointment of Dr. Klaus Hinterding as Chief Scientific O …
Martinsried, Germany, February 9, 2012. Proteros biostructures GmbH (Proteros) announced today that Dr. Klaus Hinterding, formerly at Hoffmann-La Roche Ltd. (Roche), has joined the company as Chief Scientific Officer and member of the management board. Dr. Hinterding brings to Proteros considerable pharmaceutical industry experience that spans early research through to clinical development in various therapeutic areas. At Novartis, his research contributed to the understanding of the mode-of-action of GilenyaTM, licensed for
Janssen Pharmaceutica NV and Proteros expand relationship and enter into Global …
Martinsried Jan 09, 2012. Janssen Research & Development, a division of Janssen Pharmaceutica NV (“Janssen”) and Proteros biostructures GmbH (“Proteros”) today announced they have entered into a long-term global service agreement granting Janssen privileged access to Proteros portfolio of discovery technologies and services. Under the agreement Janssen will have broad access to Proteros’ drug discovery technologies, including structural biology, biophysical screening and profiling service, novel fragment libraries, medicinal chemistry expertise and

All 5 Releases


More Releases for Proteros’

PROTEROS ANNOUNCES SUCCESSFUL CLOSE OF FINANCING ROUND
Largest-ever Financing allows for Expansion of Drug Discovery Capabilities MARTINSRIED, GERMANY (August 6th, 2012) – Proteros biostructures GmbH (‘Proteros’) announced today that it had successfully closed a financing round of five million Euros to fund the continued expansion and growth of the company. The financing round was led by BayBG, a key equity investor for Proteros. The financing round is the third and largest investment into the firm since the inception
Janssen Pharmaceutica NV and Proteros expand relationship and enter into Global …
Martinsried Jan 09, 2012. Janssen Research & Development, a division of Janssen Pharmaceutica NV (“Janssen”) and Proteros biostructures GmbH (“Proteros”) today announced they have entered into a long-term global service agreement granting Janssen privileged access to Proteros portfolio of discovery technologies and services. Under the agreement Janssen will have broad access to Proteros’ drug discovery technologies, including structural biology, biophysical screening and profiling service, novel fragment libraries, medicinal chemistry expertise and
Almirall enters into Integrated Discovery Agreement with Proteros
Barcelona, September 22, 2011. Almirall, S.A. and Proteros biostructures GmbH today announced they have entered into a research collaboration to identify small molecule inhibitors against a target selected by Almirall in the field of inflammatory diseases. Under the agreement Proteros will apply its protein structure-based drug discovery platform. Proprietary site specific screening technologies, novel fragment libraries and structural biology will be deployed to support medicinal chemistry objectives of the program, to
Rigel and Proteros renew X-ray protein crystallography collaboration
Martinsried, Germany, July 12, 2011. Proteros Biostructures GmbH (“Proteros”) announced today that it has renewed its agreement with Rigel Pharmaceuticals, Inc. (Rigel) to provide structural biology services for a Rigel drug discovery program. Under this agreement, Proteros will provide X-ray structure analysis of protein-compound complexes for specific targets to support Rigel’s discovery efforts. Proteros will deploy its high throughput crystallography platform and proprietary technologies. Proteros focuses on providing structure
Proteros and CHDI Foundation, Inc. establish discovery services collaboration to …
Martinsried, Germany, March 16, 2011. Proteros Biostructures GmbH (Proteros) announced today that it has entered into a service agreement with CHDI Foundation, Inc. (CHDI), under which Proteros will provide structure-based drug discovery services to CHDI. Proteros will apply its integrated discovery platform including proprietary X-ray crystallography tools to help CHDI in its mission to develop therapeutics that slow the progression of Huntington’s disease (HD). Cony D’Cruz Chief Business Officer and President
Proteros and SUPERGEN enter into an integrated lead discovery agreement
Martinsried, Germany, February 02, 2011. Proteros Biostructures GmbH (Proteros) announced today that it has entered into an agreement with SuperGen Inc., under which Proteros will collaborate on the discovery of small molecule lead compounds against a specific target of interest. Under the agreement, Proteros will deploy its integrated lead discovery platform that seamlessly links structural biology, screening of a tailor-made compound and fragment library, compound profiling and medicinal chemistry activities